Dr. Frank Genese, D.O
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,296 | 53 | 78.3% |
| Consulting Fee | $360.00 | 1 | 21.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $360.00 | 1 | $0 (2019) |
| GlaxoSmithKline, LLC. | $284.40 | 15 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $226.84 | 13 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $219.99 | 5 | $0 (2022) |
| Electromed, Inc. | $157.54 | 4 | $0 (2024) |
| Amgen Inc. | $110.02 | 4 | $0 (2024) |
| GENZYME CORPORATION | $105.02 | 3 | $0 (2024) |
| Grifols USA, LLC | $57.31 | 3 | $0 (2023) |
| Insmed, Inc. | $38.31 | 2 | $0 (2021) |
| Mylan Specialty L.P. | $38.31 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $229.46 | 6 | Electromed, Inc. ($104.07) |
| 2023 | $183.73 | 8 | GlaxoSmithKline, LLC. ($59.07) |
| 2022 | $237.03 | 13 | GlaxoSmithKline, LLC. ($95.99) |
| 2021 | $84.79 | 4 | GENZYME CORPORATION ($27.93) |
| 2020 | $174.29 | 9 | AstraZeneca Pharmaceuticals LP ($68.46) |
| 2019 | $746.68 | 14 | Merck Sharp & Dohme Corporation ($360.00) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $48.99 | General |
| Category: Immunology | ||||||
| 06/26/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $29.56 | General |
| Category: Inflammation | ||||||
| 04/19/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $20.86 | General |
| Category: HFCWO | ||||||
| 04/18/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $83.21 | General |
| Category: HFCWO | ||||||
| 03/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: Immunology | ||||||
| 01/18/2024 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Respiratory | ||||||
| 11/29/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: RESPIRATORY | ||||||
| 10/05/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: RESPIRATORY | ||||||
| 09/13/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $28.97 | General |
| Category: HFCWO | ||||||
| 08/09/2023 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2023 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Inflammation | ||||||
| 05/24/2023 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: Inflammation | ||||||
| 04/19/2023 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $24.50 | General |
| Category: HFCWO | ||||||
| 04/19/2023 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Pulmonology | ||||||
| 11/02/2022 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Inflammation | ||||||
| 10/06/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: IMMUNOLOGY | ||||||
| 08/31/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: IMMUNOLOGY | ||||||
| 08/11/2022 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: Rare Disease | ||||||
| 07/21/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Respiratory | ||||||
| 05/24/2022 | Mylan Specialty L.P. | Yupelri (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 04/21/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Respiratory | ||||||
| 04/18/2022 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: Pulmonology | ||||||
| 04/07/2022 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: IMMUNOLOGY | ||||||
| 03/28/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 203 | 309 | $84,069 | $25,946 |
| 2022 | 8 | 207 | 349 | $106,649 | $40,828 |
| 2021 | 9 | 247 | 436 | $133,393 | $54,107 |
| 2020 | 10 | 284 | 402 | $105,804 | $42,577 |
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 59 | 153 | $76,678 | $22,353 | 29.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 48 | $5,596 | $2,851 | 50.9% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 39 | 39 | $584.61 | $248.86 | 42.6% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 27 | 27 | $546.21 | $233.50 | 42.7% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 31 | 31 | $428.11 | $180.74 | 42.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 11 | 11 | $235.07 | $80.00 | 34.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 87 | 212 | $93,710 | $36,163 | 38.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 38 | $4,430 | $2,116 | 47.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 14 | $2,354 | $1,136 | 48.2% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 12 | 13 | $4,887 | $869.30 | 17.8% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 19 | 19 | $384.37 | $172.31 | 44.8% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 24 | 25 | $374.75 | $170.39 | 45.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 16 | 16 | $341.92 | $122.72 | 35.9% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 11 | 12 | $165.72 | $78.65 | 47.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 81 | 258 | $114,044 | $45,135 | 39.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 19 | $6,221 | $2,992 | 48.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 35 | $5,886 | $2,872 | 48.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 18 | 23 | $3,956 | $1,764 | 44.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 13 | $1,816 | $701.87 | 38.7% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 32 | 32 | $479.68 | $217.20 | 45.3% |
| 94727 | Determination of lung volumes using gas dilution or washout | Facility | 2021 | 21 | 21 | $424.83 | $185.63 | 43.7% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 24 | 24 | $331.44 | $146.74 | 44.3% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 11 | 11 | $235.07 | $92.07 | 39.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 78 | 154 | $68,073 | $26,429 | 38.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 36 | 37 | $12,114 | $5,737 | 47.4% |
About Dr. Frank Genese, D.O
Dr. Frank Genese, D.O is a Student in an Organized Health Care Education/Training Program healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/15/2013. The National Provider Identifier (NPI) number assigned to this provider is 1619310190.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frank Genese, D.O has received a total of $1,656 in payments from pharmaceutical and medical device companies, with $229.46 received in 2024. These payments were reported across 54 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,296).
As a Medicare-enrolled provider, Genese has provided services to 941 Medicare beneficiaries, totaling 1,496 services with total Medicare billing of $163,459. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Pulmonary Disease
- Location Rochester, NY
- Active Since 04/15/2013
- Last Updated 10/17/2022
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1619310190
Products in Payments
- SMARTVEST (Device) $157.54
- DUPIXENT (Biological) $133.92
- NUCALA (Biological) $123.85
- TEZSPIRE (Biological) $110.02
- TRELEGY ELLIPTA (Drug) $107.26
- SYMBICORT (Drug) $71.47
- OFEV (Drug) $66.07
- Prolastin-C Liquid (Biological) $57.31
- FASENRA (Drug) $55.92
- BREZTRI (Drug) $43.66
- Arikayce (Drug) $38.31
- Yupelri (Drug) $38.31
- ANORO (Drug) $37.36
- STIOLTO RESPIMAT (Drug) $24.49
- ANORO ELLIPTA (Drug) $15.93
- FASENRA (Biological) $15.13
- ANDEXXA (Biological) $13.21
- BREZTRI AEROSPHERE (Drug) $11.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Rochester
Dr. Yucai Wang, Md, Phd, MD, PHD
Student in an Organized Health Care Education/Training Program — Payments: $1.1M
Kevin Perry, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $675,526
Arjun Sebastian, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $132,513
Benjamin Tracy
Student in an Organized Health Care Education/Training Program — Payments: $112,594
Dr. Vijay Agarwal, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $105,512
Mr. Timothy Brown, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $89,868